(Q57905130)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Oral estramustine and oral etoposide for hormone-refractory prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

1 reference

Athanasios Dimopoulos

1

object named as

Meletios A. Dimopoulos

0 references

author name string

Dimopoulos MA

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Panopoulos C

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Bamia C

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Deliveliotis C

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Alivizatos G

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Pantazopoulos D

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Constantinidis C

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Kostakopoulos A

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Kastriotis I

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Zervas A

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Aravantinos G

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Dimopoulos C

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 November 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

754-758

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900323-3

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900323-3

7 January 2021

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900323-3

7 January 2021

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900323-3

7 January 2021

Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900323-3

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900323-3

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900323-3

7 January 2021

Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900323-3

7 January 2021

Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900323-3

7 January 2021

Oral etoposide in the treatment of hormone-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900323-3

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2897%2900323-3

7 January 2021

10.1016/S0090-4295(97)00323-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9372887%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference